Apixaban – Medxy AI

Apixaban in Subclinical Atrial Fibrillation: More Major Bleeds Driven by GI Events but Not by Intracranial or Fatal Hemorrhage

By MedXY 11/14/2025

In ARTESiA patients with device-detected subclinical AF, apixaban reduced thromboembolism but increased major bleeding—primarily noncritical gastrointestinal events—while intracranial and fatal bleeding rates were similar to aspirin.

Cardiology Neurology news

Apixaban Versus Aspirin for Recurrent Stroke Prevention in Patients with Left Ventricular Dysfunction: Insights from a Secondary Analysis of the ARCADIA Trial

By MedXY 10/29/2025

A secondary analysis of the ARCADIA trial reveals that apixaban significantly reduces recurrent ischemic stroke risk compared to aspirin in patients with left ventricular systolic dysfunction post-cryptogenic stroke.

Cardiology Internal Medicine

Optimizing Extended Apixaban Therapy for Venous Thromboembolism: Insights from Recent Randomized Trials

By MedXY 09/26/2025

Extended low-dose apixaban significantly reduces recurrent venous thromboembolism (VTE) in patients with provoked VTE and enduring risk factors, with minimal major bleeding. Reduced-dose apixaban for cancer-associated VTE is equally effective as full dose but lowers bleeding risk.

Cardiology Clinical Updates Internal Medicine news

Extended Apixaban Therapy Reduces Recurrent VTE Risk in Patients with Provoked Events and Enduring Risk Factors

By MedXY 09/26/2025

A randomized trial demonstrates that low-dose apixaban for 12 months significantly lowers symptomatic recurrent VTE risk after provoked events with enduring risk factors, with minimal major bleeding.